 Nektar Therapeutics NASDAQ: NKTR and Bristol Myers Squibb Co NYSE: BMY have jointly decided to end the global clinical development program for bempegaldesleukin in combination with Opdivo. The decision follows the results from pre-planned analyses of two late-. 